[go: up one dir, main page]

EA200601766A1 - Производные имидазола - Google Patents

Производные имидазола

Info

Publication number
EA200601766A1
EA200601766A1 EA200601766A EA200601766A EA200601766A1 EA 200601766 A1 EA200601766 A1 EA 200601766A1 EA 200601766 A EA200601766 A EA 200601766A EA 200601766 A EA200601766 A EA 200601766A EA 200601766 A1 EA200601766 A1 EA 200601766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazole derivatives
conditions
receptor
inflammation
modulating
Prior art date
Application number
EA200601766A
Other languages
English (en)
Other versions
EA011242B1 (ru
Inventor
Дэниэл Дж. Бьюзард
Джеймс П. Эдвардс
Дэвид Э. Киндрачук
Дженнифер Д. Венэйбл
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200601766A1 publication Critical patent/EA200601766A1/ru
Publication of EA011242B1 publication Critical patent/EA011242B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Производные имидазола, композиции и способы применения их при ингибировании рекрутмента лейкоцитов, при модуляции экспрессии Н-рецептора и при лечении таких состояний, как воспаление, опосредуемые Н-рецептором состояния и родственные состояния.
EA200601766A 2004-03-25 2005-03-24 Производные имидазола EA011242B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55635604P 2004-03-25 2004-03-25
PCT/US2005/009715 WO2005092066A2 (en) 2004-03-25 2005-03-24 Imidazole compounds

Publications (2)

Publication Number Publication Date
EA200601766A1 true EA200601766A1 (ru) 2007-04-27
EA011242B1 EA011242B1 (ru) 2009-02-27

Family

ID=35056771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601766A EA011242B1 (ru) 2004-03-25 2005-03-24 Производные имидазола

Country Status (18)

Country Link
US (9) US7253200B2 (ru)
EP (1) EP1737297B1 (ru)
JP (1) JP5162236B2 (ru)
KR (1) KR101217103B1 (ru)
CN (1) CN101022728B (ru)
AU (1) AU2005226729B2 (ru)
BR (1) BRPI0509164A (ru)
CA (1) CA2560896C (ru)
CR (1) CR8704A (ru)
EA (1) EA011242B1 (ru)
EC (1) ECSP066882A (ru)
IL (2) IL178287A (ru)
MX (1) MXPA06011021A (ru)
NO (1) NO20064848L (ru)
NZ (1) NZ550087A (ru)
UA (1) UA89226C2 (ru)
WO (1) WO2005092066A2 (ru)
ZA (1) ZA200608836B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011021A (es) * 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US7589087B2 (en) * 2006-03-31 2009-09-15 Janssen Pharmaceutica, N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor
ME01143B (me) 2006-03-31 2013-03-20 Janssen Pharmaceutica Nv BENZOIMIDAZOL-2-IL PIRIMIDINI l PIRAZINI KAO MODULATORI HISTAMINSKOG H4 RECEPTORA
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
CL2007002007A1 (es) * 2006-07-11 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de benzofuro y benzotienopirimidinas, moduladores del receptor de histamina h4; procedimiento de preparacion; y su uso para tratar trastornos inflamatorios, alergicos, dermatologicos, enfermedades autoinmune, linfaticas y de inmu
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
JP5439377B2 (ja) * 2007-09-14 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のチエノ−及びフロ−ピリミジン調節物質
WO2009079001A1 (en) * 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
NZ603074A (en) 2008-06-12 2013-08-30 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2865678A3 (en) * 2008-06-30 2015-05-27 Janssen Pharmaceutica NV Crystalline hemi-tartrate form of a benzoimidazol-2-yl pyrimidine derivative
CA2742366C (en) * 2008-12-01 2020-09-22 Targacept, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
UA103699C2 (ru) 2009-08-20 2013-11-11 Еда Рисёрч Энд Девелопмент Ко., Лтд. Терапия глатирамера ацетатом с низкой частотой
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
TW201348235A (zh) 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187213A (en) * 1978-01-09 1980-02-05 Eastman Kodak Company Multiheterocyclic ultraviolet stabilizers and their use in organic compositions
FR2665161B1 (fr) * 1990-07-26 1992-11-27 Esteve Labor Dr Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
EP0994870A4 (en) * 1997-06-19 2002-10-23 Smithkline Beecham NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
DE59911249D1 (de) * 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
KR100852362B1 (ko) * 2000-08-08 2008-08-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시피페리딘
DE60309342T2 (de) * 2002-08-09 2007-05-16 Eli Lilly And Co., Indianapolis Benzimidazole und benzothiazole als inhibitoren der map-kinase
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
US20040229927A1 (en) * 2003-04-10 2004-11-18 Sircar Jagadish C. Imidazole derivatives for treatment of allergic and hyperproliferative disorders
KR20060097024A (ko) * 2003-09-30 2006-09-13 얀센 파마슈티카 엔.브이. 벤조이미다졸 화합물
MXPA06011021A (es) * 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.

Also Published As

Publication number Publication date
US7956057B2 (en) 2011-06-07
JP5162236B2 (ja) 2013-03-13
IL178287A0 (en) 2006-12-31
US20070173510A1 (en) 2007-07-26
CA2560896C (en) 2013-06-18
IL178287A (en) 2012-12-31
CR8704A (es) 2008-11-24
US8039498B2 (en) 2011-10-18
EP1737297B1 (en) 2012-12-19
CA2560896A1 (en) 2005-10-06
WO2005092066A3 (en) 2006-01-12
WO2005092066A2 (en) 2005-10-06
ECSP066882A (es) 2006-11-24
US20050261309A1 (en) 2005-11-24
KR101217103B1 (ko) 2012-12-31
US8017600B2 (en) 2011-09-13
IL205159A0 (en) 2010-11-30
US20070173509A1 (en) 2007-07-26
MXPA06011021A (es) 2007-04-13
EP1737297A4 (en) 2009-07-15
UA89226C2 (en) 2010-01-11
HK1102020A1 (en) 2007-11-02
US7928131B2 (en) 2011-04-19
US7956066B2 (en) 2011-06-07
US8017639B2 (en) 2011-09-13
US20100261898A1 (en) 2010-10-14
AU2005226729A1 (en) 2005-10-06
US20070265250A1 (en) 2007-11-15
NO20064848L (no) 2006-10-25
AU2005226729B2 (en) 2010-01-28
CN101022728A (zh) 2007-08-22
US20070173512A1 (en) 2007-07-26
US7253200B2 (en) 2007-08-07
EA011242B1 (ru) 2009-02-27
US20070149541A1 (en) 2007-06-28
CN101022728B (zh) 2012-08-08
US20070173513A1 (en) 2007-07-26
KR20070021186A (ko) 2007-02-22
WO2005092066A8 (en) 2007-03-29
BRPI0509164A (pt) 2007-09-11
JP2007530570A (ja) 2007-11-01
US7956071B2 (en) 2011-06-07
NZ550087A (en) 2009-06-26
ZA200608836B (en) 2008-05-28
EP1737297A2 (en) 2007-01-03
US20100261899A1 (en) 2010-10-14
US7951808B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
EA200601766A1 (ru) Производные имидазола
NL301145I2 (nl) Tirbanibulin
EA200900571A1 (ru) Композиции chk1 ингибиторов
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201170521A1 (ru) Новые соединения
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA201170227A1 (ru) Имидазолкарбоксамиды
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
BRPI0513310A (pt) análogos de tetrapeptìdeo
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201000329A1 (ru) Циклические депсипептиды
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA201100874A1 (ru) Соединения для лечения рака
EA200970818A1 (ru) Гетероциклические соединения, содержащие их композиции и способы их применения